01 什么是溶瘤病毒? 图1 目前临床研究的肿瘤免疫疗法[6] 02 溶瘤病毒种类及基因改造 图2 溶瘤病毒的种类 图3 溶瘤病毒的基因改造 03 溶瘤治疗的机制 图4 溶瘤病毒作用机制 04 溶瘤病毒治疗的研究现状 表1 CDE官网部分申报临床的溶瘤病毒试验信息 (向下滑动查看) 05 溶瘤病毒的联合治疗 06 总结与展望 作者| 喻松霞 编辑| 吴明兰 审核| 胡兴江 刘 健 赵青威 [1].GUJAR S, BELL J, DIALLO J S. SnapShot: cancer immunotherapy with oncolytic viruses[J]. Cell, 2019, 176(5): 1240-1240. e1. [2].BELL J C, MCFADDEN G. Editorial overview: oncolytic virusesreplicating virus therapeutics for the treatment of cancer[J]. Curr Opin Virol, 2015, 13:viii-ix. DOI:10.1016/j.coviro.2015.07.005. [3].HARRINGTON K J, KONG A, MACH N, et al. Talimogene laherparepvec and pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (MASTERKEY-232): a multicenter, phase 1b study[J]. Clin Cancer Res, 2020, 26(19): 5153-5161. [4].张晓, 李幸, 汪治宇. 溶瘤病毒联合免疫检查点抑制剂在恶性黑 色素瘤中的应用[J]. 中国肿瘤生物治疗杂志, 2019, 26(2): 241- 245. DOI:10.3872/j.issn.1007-385x.2019.02.017 [5].GUEDAN S, ALEMANY R. CAR-T cells and oncolytic viruses: joining forces to overcome the solid tumor challenge[J]. Front Immunol, 2018,9:2460. DOI: 10.3389/fimmu.2018.0246 [6].李龙,谢成英,郑明月等.肿瘤免疫治疗研究进展[J].自然杂志。2021,43(6). DOI: 10.3969/j.issn.0253-9608.2021.06.001 [7]. Lan Q, Xia S, Wang Q, Lu L et al. Development of oncolytic virotherapy: from genetic modification to combination therapy[J]. Front Med 2020 Apr;14(2). https:///10.1007/s11684-020-0750-4 [8].MACEDO N, MILLER D M, HAQ R, et al. Clinical landscape of oncolytic virus research in 2020[J]. J Immunother Cancer, 2020, 8(2): e001486 [9].Hamid O, Hoffner B, Gasal E, et al. Oncolytic immunotherapy:unlocking the potential of viruses to help target cancer. Cancer Immunol Immunother.2017, 66(10):1249. [10].药审中心.《溶瘤病毒类药物临床试验设计指导原则》.2020年8月 [11].N.H. Goradel, A.T. Baker and A. Arashkia et al., Oncolytic virotherapy: Challenges and solutions, Current Problems in Cancer, https:///10.1016/j.currproblcancer.2020.100639 [12].HIROOKA Y, KASUYA H, ISHIKAWA T, et al. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer[J]. BMC Cancer, 2018,18(1):596. DOI: 10.1186/s12885-018-4453-z. [13].Markert JM, Razdan SN, Kuo HC, et al. A phase Ⅰ trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses[J]. Mol Ther, 2014, 22(5):1048-1055 [14].Ribas A, Dummer R, Puzanov I,et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 2017; 170(6): 1109–1119.e10 [15].Park AK, Fong Y, Kim SI,et al.Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors[J]. Sci Transl Med 2020 09 02;12(559) |
|